Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;18(3-4):339-46.
doi: 10.1007/s12640-010-9175-1. Epub 2010 Mar 30.

Progression of atrophy in Alzheimer's disease and related disorders

Affiliations
Review

Progression of atrophy in Alzheimer's disease and related disorders

Jennifer L Whitwell. Neurotox Res. 2010 Nov.

Abstract

Longitudinal MRI is a powerful tool that allows the assessment of progression of brain changes over multiple imaging time-points and has been increasingly employed in the study of neurodegenerative dementias, particularly Alzheimer's disease (AD). Early studies demonstrated that AD was associated with increased rates of whole brain loss and hippocampal atrophy. A number of sophisticated voxel-level techniques have now been developed that have provided additional information describing regional atrophy over time in the temporal, parietal, and frontal lobes in AD. Studies have also focused on subjects in the prodromal phase of AD in order to describe the earliest changes that are occurring in the brain. Atrophy has been shown to start in the medial temporal lobes and fusiform gyrus at least 3 years before subjects reach a diagnosis of AD, and then spread to the posterior temporal lobes and parietal lobes, and then eventually the frontal lobes. These patterns of atrophy correlate well with the progression of neurofibrillary tangles observed on pathology. Rates of atrophy have also been shown to accelerate over the course of the disease as a subject progresses from cognitively normal to a diagnosis of AD. Similar techniques have also been applied to other neurodegenerative diseases, such as frontotemporal dementia which show higher rates of atrophy and different patterns of progression to those observed in AD. Hence, longitudinal MRI shows promise as a biomarker of disease progression in neurodegenerative disease.

PubMed Disclaimer

References

    1. Lancet Neurol. 2006 Oct;5(10):828-34 - PubMed
    1. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):441-7 - PubMed
    1. Magn Reson Med. 2001 Oct;46(4):661-6 - PubMed
    1. Neurology. 2004 Feb 24;62(4):591-600 - PubMed
    1. Neurology. 2005 May 10;64(9):1563-72 - PubMed

LinkOut - more resources